

21st November 2007

TIME.L

Timestrip plc

DHL successfully trial Timestrip® and iStrip®

Timestrip plc is pleased to announce that its Timestrip® and iStrip® label technologies have been successfully trialled in a pilot project with DHL, one of the world's leading logistics companies, to monitor temperatures of sensitive products such as medical vaccinations during transportation.

The iStrip® is a patent pending label developed by Timestrip plc which undergoes an irreversible colour change when exposed to freezing temperatures. It is designed to be mass-produced at low cost and to be fully integrated into the packaging of products such as vaccines, protein based pharmaceuticals, foodstuffs and fertilizer.

The trial was focused on improving the transportation of sensitive products in order to ensure that the correct temperature conditions were maintained throughout the critical storage and transportation process. Correct storage temperatures are key to this process as up to 50% of problems with the transportation of medical health care products for example are due to incorrect storage temperatures.

The DHL project has successfully demonstrated the benefit of the Timestrip® and iStrip® technologies, not only in monitoring optimum transport temperatures but also in identifying, when problems do occur, which particular parts of a pallet or shipment have been adversely affected. This allows targeted disposal of affected products, reducing the need to destroy a product that may be scarce or valuable.

Commenting on the trial, Mike Meakin, Quality Director, Healthcare EMEA, DHL Exel said:

“One of the biggest challenges currently facing logistics companies is temperature assurance in frozen, chilled and temperate conditions. It is now clear that we can use Timestrip and iStrip® labels to highlight whether a temperature limit could have been breached. As a consequence, we have been able to find a cost-effective way to enhance quality assurance.”

Reuben Isbitsky, Joint CEO of Timestrip plc, said:

“We are delighted to have been involved in this pilot trial with DHL that has confirmed the unique and far-reaching benefits that our label technologies can bring to companies transporting pharmaceutical and related healthcare products. I look forward to being able to announce further details of developments with DHL in the future.”

For more information, please contact:

Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc	01462 440 700
Shane Dolan, Biddicks	020 7448 1000
Fergus Marcroft, Evolution Securities	020 7071 4300